QS Investors’s Sciclone Pharmaceuticals Inc SCLN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2017
Q4 | – | Sell |
-409,912
| Closed | -$4.59M | – | 2042 |
|
|
2017
Q3 | $4.59M | Sell |
409,912
-28,695
| -7% | -$317K | 0.04% | 338 |
|
|
2017
Q2 | $4.83M | Sell |
438,607
-4,934
| -1% | -$49.4K | 0.04% | 323 |
|
|
2017
Q1 | $4.35M | Sell |
443,541
-3,911
| -0.9% | -$39.1K | 0.04% | 345 |
|
|
2016
Q4 | $4.83M | Sell |
447,452
-182,078
| -29% | -$1.82M | 0.04% | 350 |
|
|
2016
Q3 | $6.45M | Hold |
629,530
| – | – | 0.05% | 300 |
|
|
2016
Q2 | $8.22M | Sell |
629,530
-8,407
| -1% | -$110K | 0.07% | 247 |
|
|
2016
Q1 | $7.02M | Sell |
637,937
-11,916
| -2% | -$106K | 0.07% | 290 |
|
|
2015
Q4 | $5.98M | Sell |
649,853
-15,836
| -2% | -$133K | 0.06% | 324 |
|
|
2015
Q3 | $4.62M | Sell |
665,689
-160,792
| -19% | -$1.38M | 0.05% | 388 |
|
|
2015
Q2 | $8.12M | Buy |
826,481
+143,700
| +21% | +$1.31M | 0.1% | 248 |
|
|
2015
Q1 | $6.05M | Sell |
682,781
-10,800
| -2% | -$86K | 0.07% | 314 |
|
|
2014
Q4 | $6.08M | Buy |
+693,581
| New | +$5.61M | 0.07% | 309 |
|
|
2013
Q3 | – | Sell |
-14,500
| Closed | -$72K | – | 697 |
|
|
2013
Q2 | $72K | Buy |
+14,500
| New | +$69K | ﹤0.01% | 636 |
|
QS Investors's SCLN Position: Q4 2017 in Review
QS Investors sold out of Sciclone Pharmaceuticals Inc (SCLN) in Q4 2017, closing a stake of 409,912 shares — an estimated $4.59M sold.
QS Investors first reported a position in SCLN in Q2 2013 and held it in 13 quarters. The position peaked at $8.22M in Q2 2016. 0 funds tracked by Wall St. Rank hold SCLN as of Q4 2017.
- QS Investors reported no remaining Sciclone Pharmaceuticals Inc position as of Q4 2017 after selling out during the quarter.
- QS Investors sold 409,912 Sciclone Pharmaceuticals Inc shares in Q4 2017, an estimated $4.59M.
- QS Investors first reported a position in Sciclone Pharmaceuticals Inc in Q2 2013 and held it in 13 quarters.
- QS Investors's Sciclone Pharmaceuticals Inc position peaked at $8.22M in Q2 2016.
- 0 funds tracked by Wall St. Rank held Sciclone Pharmaceuticals Inc as of Q4 2017.
Based on QS Investors's 13F filing for Q4 2017, filed 14 Feb 2018.